Microbial Diversity
Bacterial and Fungal Diversity
Traditional qPCR and pathogen array approaches are limited to a pre-defined set of approximately 25 to 40 microorganisms. These technologies can only detect what they are designed for to investigate. However, the diversity of microbial etiologies of diseases like sepsis, meningitis, endocarditis, or arthritis is significantly higher, including more than 130 bacterial and fungal strains. Broad-range detection and identification approaches like 16S rRNA gene PCR are potentially useful to analyze any pathogen present in a clinical sample. By the enrichment of pathogen DNA from samples, SepsiTest™ overcomes the common constraints of broad-range approaches, i.e., low sensitivity and specificity by nonspecific signal generation from human sequences. As a result, an up to 40,000-times higher sensitivity is obtained as compared to conventional 16S approaches.
Based on Molzym’s SepsiTest™ technology, pathogen DNA is available to next-generation sequencing (NGS) technologies. We deliver the following information:
Based on Molzym’s SepsiTest™ technology, pathogen DNA is available to next-generation sequencing (NGS) technologies. We deliver the following information:
|
 |
Case Study:
|
As part of a pre-clinical study, a drug developer was investigating a drug candidate reducing viral loads in respiratory organs. In addition, the company was interested in exploring the drug’s potential for reducing microbial colonization of the upper respiratory tract. Molzym’s Clinical Services developed a protocol assessing pre-dose and post-dose bacterial colonization. The assay was successfully validated and is now ready for bioanalysis of phase I samples.
|